In Vitro Effects of Alternative Chemotherapeutics on a Virulent Strain of the Bovine Parasite Tritrichomonas foetus
Poster Number
28
Format
Poster Presentation
Abstract/Artist Statement
Tritrichomonas foetus is a protozoan responsible for bovine trichomoniasis. Trichomoniasis in cattle is a disease characterized by self-limitation, and infects both male and female cows, with bulls being asymptomatic chronic carriers of the disease. Similar to trichomoniasis in humans, the protozoan can be treated in vitro using nitroimidazole drugs and its derivatives. However, nitroimidazole drugs are no longer approved by the FDA for treatment of bovine trichomoniasis. Currently, trichomoniasis has a prevalence of disease as high as 16% in natural-breeding range herds and the lack of pharmacological treatment for the disease as well as the impracticality of current control methods contribute to the necessity for new, more effective chemotherapeutics. In order to support the effort we have started to screen, in vitro, a compound library of 3,4- dichloroaniline amides, of which only a couple of shown promise for inhibition of parasite growth. Further trials of these compounds will confirm which compounds show promising ability at inhibiting parasite growth, at which point IC50 values will be determined for these compounds, as well as structure-activity relationships.
Location
DeRosa University Center, Ballroom B
Start Date
2-5-2009 1:00 PM
End Date
2-5-2009 3:00 PM
In Vitro Effects of Alternative Chemotherapeutics on a Virulent Strain of the Bovine Parasite Tritrichomonas foetus
DeRosa University Center, Ballroom B
Tritrichomonas foetus is a protozoan responsible for bovine trichomoniasis. Trichomoniasis in cattle is a disease characterized by self-limitation, and infects both male and female cows, with bulls being asymptomatic chronic carriers of the disease. Similar to trichomoniasis in humans, the protozoan can be treated in vitro using nitroimidazole drugs and its derivatives. However, nitroimidazole drugs are no longer approved by the FDA for treatment of bovine trichomoniasis. Currently, trichomoniasis has a prevalence of disease as high as 16% in natural-breeding range herds and the lack of pharmacological treatment for the disease as well as the impracticality of current control methods contribute to the necessity for new, more effective chemotherapeutics. In order to support the effort we have started to screen, in vitro, a compound library of 3,4- dichloroaniline amides, of which only a couple of shown promise for inhibition of parasite growth. Further trials of these compounds will confirm which compounds show promising ability at inhibiting parasite growth, at which point IC50 values will be determined for these compounds, as well as structure-activity relationships.